12:00 AM
 | 
Aug 07, 2000
 |  BC Week In Review  |  Company News  |  Deals

Xenogen Inc., Novartis deal

Under a three year license, NOVN will use Xenogen's biophotonic in vivo imaging technology for...

Read the full 55 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >